Smith, Kline & French
Smith, Kline & French (SKF) was an American pharmaceutical company, known for its innovative contributions to the healthcare industry. It was founded in 1830 by Mahlon Kline and John K. Smith in Philadelphia, Pennsylvania. The company was later acquired by GlaxoSmithKline in 2000.
History
SKF was established in 1830 by Mahlon Kline and John K. Smith as a drugstore in Philadelphia. The company initially focused on the production of drugs and pharmaceuticals. In 1865, the company was incorporated as Smith, Kline & Co. and expanded its operations to include the manufacturing of pharmaceuticals.
In 1891, the company merged with French, Richards & Co., becoming Smith, Kline & French. The company continued to grow and innovate, introducing products such as Thorazine (chlorpromazine), the first widely used antipsychotic, and Dexedrine (dextroamphetamine), a stimulant used to treat ADHD and narcolepsy.
In 1989, Smith, Kline & French merged with Beecham Group, a British pharmaceutical company, to form SmithKline Beecham. The merger was one of the largest in the pharmaceutical industry at the time. In 2000, SmithKline Beecham merged with Glaxo Wellcome to form GlaxoSmithKline, one of the world's leading pharmaceutical companies.
Contributions to Healthcare
Smith, Kline & French made significant contributions to the healthcare industry. The company was known for its innovative research and development. It introduced several groundbreaking drugs, including Thorazine and Dexedrine, which had a significant impact on the treatment of mental health disorders and attention deficit hyperactivity disorder (ADHD), respectively.
Legacy
Today, the legacy of Smith, Kline & French lives on in GlaxoSmithKline. The company continues to be a leader in the pharmaceutical industry, with a strong commitment to research and development, and a broad portfolio of innovative medicines.
See Also

This article is a pharmacology-related stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian